Uptake during an oral cholera vaccine pilot demonstration program, Odisha, India

Kar, Shantanu Kumar; Pach, Alfred; Sah, Binod; Kerketta, Anna S.; Patnaik, Bikash; Mogasale, Vijayalaxmi V.; Kim, Yang‐Hee; Rath, Shyam Bandhu; Shin, Sunheang; Khuntia, Hemant Kumar; Bhattachan, Anuj; Puri, Mahesh; Wierzba, Thomas F.; Kaljee, Linda

doi:10.4161/21645515.2014.971655

Cited by 13 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All houses in the 9 selected villages were further stratified by 1) all or some household members taking two doses, 2) at least one household member receiving one dose, and 3) no household members receiving the vaccine. In total, 600 households, 200 from each of three categories (two doses, one dose and no dose) were randomly selected for conducting the socio-behavioral survey presented elsewhere [ 36 ]. The private costing questionnaire described here was administered to the subset of households that received one or two doses of vaccines only.…”

Section: Methodsmentioning

confidence: 99%

An Estimation of Private Household Costs to Receive Free Oral Cholera Vaccine in Odisha, India

et al. 2015

Self Cite

View full text Add to dashboard Cite

BackgroundService provider costs for vaccine delivery have been well documented; however, vaccine recipients’ costs have drawn less attention. This research explores the private household out-of-pocket and opportunity costs incurred to receive free oral cholera vaccine during a mass vaccination campaign in rural Odisha, India.MethodsFollowing a government-driven oral cholera mass vaccination campaign targeting population over one year of age, a questionnaire-based cross-sectional survey was conducted to estimate private household costs among vaccine recipients. The questionnaire captured travel costs as well as time and wage loss for self and accompanying persons. The productivity loss was estimated using three methods: self-reported, government defined minimum daily wages and gross domestic product per capita in Odisha.FindingsOn average, families were located 282.7 (SD = 254.5) meters from the nearest vaccination booths. Most family members either walked or bicycled to the vaccination sites and spent on average 26.5 minutes on travel and 15.7 minutes on waiting. Depending upon the methodology, the estimated productivity loss due to potential foregone income ranged from $0.15 to $0.29 per dose of cholera vaccine received. The private household cost of receiving oral cholera vaccine constituted 24.6% to 38.0% of overall vaccine delivery costs.InterpretationThe private household costs resulting from productivity loss for receiving a free oral cholera vaccine is a substantial proportion of overall vaccine delivery cost and may influence vaccine uptake. Policy makers and program managers need to recognize the importance of private costs and consider how to balance programmatic delivery costs with private household costs to receive vaccines.

show abstract

Section: Methodsmentioning

confidence: 99%

An Estimation of Private Household Costs to Receive Free Oral Cholera Vaccine in Odisha, India

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…1). [12][13] In this paper, we explore barriers and facilitators for US older adults in relation to influenza and pneumococcal vaccine up-take focused on: 1) healthcare access and utilization; 2) information resources and trust in those resources; 3) social networks and norms for vaccine use; 4) experiences and perceptions regarding influenza and pneumonia; and, 5) experiences and perceptions regarding vaccines in general and seasonal influenza and pneumococcal vaccines.…”

Section: Introductionmentioning

confidence: 99%

“You need to be an advocate for yourself”: Factors associated with decision-making regarding influenza and pneumococcal vaccine use among US older adults from within a large metropolitan health system

Kaljee

Kilgore

Prentiss

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In the United States, influenza and pneumonia account significantly to emergency room use and hospitalization of adults >65 y. The Centers for Disease Control and Prevention recommends use of the annual influenza vaccine and 2 pneumococcal vaccines for older adults to decrease risks of morbidity and mortality. However, actual vaccine up-take is estimated at 61.3% for pneumococcal vaccines and 65% for influenza vaccine in the 2013-2014 season. Vaccine up-take is affected by multiple socio-cultural and economic factors including general healthcare access and utilization, social networks and norms, communication with health providers and health information sources, as well as perceptions related to vaccines and targeted diseases. In this study, 8 focus group discussions (total N = 48) were conducted with adults 65+ years living in urban and suburban communities in the Detroit Metropolitan Area. The research objective was to increase understanding of barriers and facilitators to vaccine up-take in this age cohort within the context of general healthcare availability and accessibility, social networks, information sources, and personal perceptions of diseases and vaccines. The data suggest the need to integrate broader health care service experiences, concepts of knowledge of one's own well-being and vulnerabilities, and self-advocacy as factors associated with older adults' vaccine-use decisions. These data also support recognition of multiple levels of vaccine acceptance which can be disease specific. Implications include potential for increasing vaccine up-take through general improvement in health care delivery and services, as well as specific vaccine-focused patient and provider education programs.

show abstract

“…The OCV vaccination study is use of Shanchol™ in an endemic public health setting in Africa. Shanchol™ was introduced through the public health setting in Odisha State, India in 2011 and cholera vaccination was found to be acceptable, feasible 6 , 16 and effective although vaccination recipients bore significant indirect costs. 18 As with Odisha, we found oral cholera vaccination was feasible and acceptable in Ethiopia, as suggested by the sufficient vaccination coverage.…”

Section: Discussionmentioning

confidence: 99%

“… 15 In India, the vaccine was administered through the public health system, demonstrating the feasibility, acceptability and effectiveness of Shanchol in routine use. 6 , 11 , 16 Although the vaccine was used in outbreaks and emergency settings in Africa, the feasibility, acceptability and cost of cholera vaccination campaigns have not been studied in endemic African settings. Ethiopia is the second most populous country in sub-Saharan Africa and is cholera-endemic, with more than 100,000 cases occurring annually.…”

Section: Introductionmentioning

confidence: 99%

Feasibility and costs of a targeted cholera vaccination campaign in Ethiopia

Teshome

Desai

Kim

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Shanchol™, a WHO-prequalified oral cholera vaccine (OCV), has been used to control endemic cholera in Asia, as well as in emergencies and outbreaks elsewhere. The vaccine has not been used by public health systems in cholera-endemic settings of Africa although several outbreak response campaigns have been conducted. Here we present experiences from a mass vaccination campaign in a cholera-endemic setting of Ethiopia in which Shanchol™ was introduced through the public health system. The vaccination site was selected based on cholera cases reported in previous years. Social mobilization involved sensitization of community leaders, household visits, and mass distribution of banners, posters and leaflets. The vaccination was implemented after careful microplanning of logistics and cold chain, manpower, transportation, vaccine supply and supervision and monitoring of adverse events. Vaccine administration was recorded on individual vaccination cards. Vaccine delivery costs were collected and analyzed after vaccination. As there was no experience with Shanchol™ in Ethiopia, a bridging trial was conducted to demonstrate safety and immunogenicity of the vaccine in the local population prior to the mass vaccination. Oral cholera vaccination was conducted in two rounds of four days each in February 2015 and March 2015 in 10 selected villages of Shashemenae rural district of Ethiopia. A total of 62,161 people targeted. 47,137 people (76%) received the first dose, and 40,707 (65%) received two doses. The financial cost of the vaccination campaign was estimated at US $2·60 per dose or US $5·64 per fully immunized person. The cost of vaccine delivery excluding vaccine procurement was $0·68 per dose or $1·48 per fully immunized person. The study demonstrates that mass cholera vaccination administered through the public health system in Ethiopia is feasible, can be implemented through the existing health system at an affordable cost, and the vaccine is acceptable to the community. The lessons from this study are useful for deploying OCV in other African endemic settings through the public health system and may guide future immunization policy decisions.

show abstract

Uptake during an oral cholera vaccine pilot demonstration program, Odisha, India

Cited by 13 publications

References 19 publications

An Estimation of Private Household Costs to Receive Free Oral Cholera Vaccine in Odisha, India

An Estimation of Private Household Costs to Receive Free Oral Cholera Vaccine in Odisha, India

“You need to be an advocate for yourself”: Factors associated with decision-making regarding influenza and pneumococcal vaccine use among US older adults from within a large metropolitan health system

Feasibility and costs of a targeted cholera vaccination campaign in Ethiopia

Contact Info

Product

Resources

About